1. Home
  2. Detail

@noeliiaa.smrc:

noelia
noelia
Open In TikTok:
Region: ES
Thursday 10 September 2026 21:43:36 GMT
147
1
0
1

Music

Download

No Watermark .mp4 (1.38MB) No Watermark(HD) .mp4 (1.38MB) Watermark .mp4 (0MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @noeliiaa.smrc, please go to the Tikwm homepage.

Other Videos
#videoviraltiktok #policiaestatal🇲🇽👮🏻‍♂️ #hermanosdesangreazul
#videoviraltiktok #policiaestatal🇲🇽👮🏻‍♂️ #hermanosdesangreazul
xixixi love u #fyp#photolive#4u#fypage#foryou
xixixi love u #fyp#photolive#4u#fypage#foryou
#foryoupageofficial #sahiwalian #foryoupage
#foryoupageofficial #sahiwalian #foryoupage
Are GLP-1 receptor agonists (like semaglutide and tirzepatide) doing more than just driving weight loss and glycemic control? Emerging observational studies and clinical trials suggest they may reduce the incidence of obesity-associated cancers and improve overall survival in active cancer patients! Let's break down the scientific mechanisms: 🩺🫁👇 Hi, I'm Dr. Cleo Riles, Harvard-trained cancer researcher and science communicator. Welcome to Part 1 of my ongoing GLP-1s & Cancer Research Series: 🧬 1. THE METABOLIC & TUMOR INTERSECTION: 13 Obesity-Associated Cancers: Obesity drives chronic low-grade inflammation, hyperinsulinemia, elevated IGF-1 (insulin-like growth factor 1), and altered adipokines (leptin/adiponectin ratio)—all of which promote tumor cell proliferation and angiogenesis. Direct vs. Indirect Pathways: GLP-1s lower cancer risk indirectly through substantial adiposity loss and improved insulin sensitivity. However, researchers are also investigating direct GLP-1 receptor signalling in immune cells (e.g., NK cell restoration) and tumor microenvironments. 📊 2. WHAT THE EARLY SIGNALS SHOW: Incidence Reduction: Large retrospective cohort studies show significant risk reductions in colorectal, pancreatic, endometrial, ovarian, and breast cancers compared to traditional anti-diabetic medications like insulin or sulfonylureas. Active Cancer Outcomes: Emerging studies are evaluating whether GLP-1 use during or after active treatment improves recurrence-free survival (RFS) and treatment response (e.g., reversing chemotherapy resistance driven by metabolic dysfunction). 🔬 3. WHAT TO WATCH FOR IN THIS SERIES: Over the next several weeks, I'll be breaking down landmark studies, real-world comparative effectiveness data, and my own upcoming research presentation on GLP-1 use and breast cancer outcomes! 👇 What questions do you have about GLP-1 medications and cancer risks? Leave them below! #GLP1 #Oncology #CancerResearch #Ozempic #Wegovy
Are GLP-1 receptor agonists (like semaglutide and tirzepatide) doing more than just driving weight loss and glycemic control? Emerging observational studies and clinical trials suggest they may reduce the incidence of obesity-associated cancers and improve overall survival in active cancer patients! Let's break down the scientific mechanisms: 🩺🫁👇 Hi, I'm Dr. Cleo Riles, Harvard-trained cancer researcher and science communicator. Welcome to Part 1 of my ongoing GLP-1s & Cancer Research Series: 🧬 1. THE METABOLIC & TUMOR INTERSECTION: 13 Obesity-Associated Cancers: Obesity drives chronic low-grade inflammation, hyperinsulinemia, elevated IGF-1 (insulin-like growth factor 1), and altered adipokines (leptin/adiponectin ratio)—all of which promote tumor cell proliferation and angiogenesis. Direct vs. Indirect Pathways: GLP-1s lower cancer risk indirectly through substantial adiposity loss and improved insulin sensitivity. However, researchers are also investigating direct GLP-1 receptor signalling in immune cells (e.g., NK cell restoration) and tumor microenvironments. 📊 2. WHAT THE EARLY SIGNALS SHOW: Incidence Reduction: Large retrospective cohort studies show significant risk reductions in colorectal, pancreatic, endometrial, ovarian, and breast cancers compared to traditional anti-diabetic medications like insulin or sulfonylureas. Active Cancer Outcomes: Emerging studies are evaluating whether GLP-1 use during or after active treatment improves recurrence-free survival (RFS) and treatment response (e.g., reversing chemotherapy resistance driven by metabolic dysfunction). 🔬 3. WHAT TO WATCH FOR IN THIS SERIES: Over the next several weeks, I'll be breaking down landmark studies, real-world comparative effectiveness data, and my own upcoming research presentation on GLP-1 use and breast cancer outcomes! 👇 What questions do you have about GLP-1 medications and cancer risks? Leave them below! #GLP1 #Oncology #CancerResearch #Ozempic #Wegovy
SMS করতে করতে কাঁদছেন কখনো #😭💔 #fyp
SMS করতে করতে কাঁদছেন কখনো #😭💔 #fyp

About

Legal